Microcap Ledger Filana Therapeutics, Inc. $FLNA
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Austin, TX
- Fiscal year end
- December 31
- Shares outstanding
- 48,307,896 [10-Q 2026-05-07]
What the company doesAI summary of filing
Filana Therapeutics is a clinical-stage biotechnology company developing simufilam, a small-molecule oral drug candidate targeting filamin A for treatment of tuberous sclerosis complex (TSC)-related epilepsy and other central nervous system disorders. The company previously conducted clinical trials of simufilam for Alzheimer's disease, enrolling over 2,000 patients across Phase 1, Phase 2, and Phase 3 studies, but discontinued this program in early 2025 after both Phase 3 trials failed to meet efficacy endpoints; simufilam demonstrated a favorable safety profile throughout these trials. Filana owns or controls worldwide rights to simufilam through issued patents and pending applications, and in February 2025 entered into an exclusive worldwide license agreement with Yale University for additional intellectual property related to simufilam development. The company is currently pursuing clinical development in TSC-related epilepsy but received a clinical hold from the FDA in December 2025 pending additional preclinical data and protocol modifications. [10-K 2026-03-12]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 3 months to Mar 2026 | — | −$10.33M | −$8.88M | $86.57M | [10-Q 2026-05-07] |
| FY ended Dec 2025 | — | −$90.97M | −$32.25M | $95.50M | [DEF 14A 2026-04-28] |
| FY ended Dec 2024 | — | −$24.34M | −$116.93M | $128.57M | [DEF 14A 2026-04-28] |
- Quarterly cash burn
- −$8.88M
- Cash runway Estimate
- ~29.3 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-08-05 | 47,976,166 | [10-Q 2024-08-08] |
| 2024-11-04 | 48,110,475 | [10-Q 2024-11-07] |
| 2025-02-27 | 48,307,896 | [10-K 2025-03-03] |
| 2025-05-05 | 48,307,896 | [10-Q 2025-05-08] |
| 2025-08-12 | 48,307,896 | [10-Q 2025-08-14] |
| 2025-11-10 | 48,307,896 | [10-Q 2025-11-12] |
| 2026-03-09 | 48,307,896 | [10-K 2026-03-12] |
| 2026-05-04 | 48,307,896 | [10-Q 2026-05-07] |
- Shelf registration
- S-3 filed 2025-11-13; declared effective 2025-12-05 [S-3 2025-11-13]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-09-18. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-09-18 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-09-18] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-30 | Barry Richard | buy | 100,000 | $0.92 | [4 2026-10-01] |
| 2026-09-29 | Barry Richard | buy | 206,813 | $0.90 | [4 2026-10-01] |
| 2026-09-28 | Barry Richard | buy | 93,091 | $0.84 | [4 2026-09-30] |
| 2025-11-24 | Anderson Robert Eugene Jr | buy | 8,600 | $2.90 | [4 2025-11-25] |
| 2025-11-20 | Barry Richard | buy | 150,000 | $2.76 | [4 2025-11-24] |
| 2025-11-19 | Barry Richard | buy | 73,385 | $2.75 | [4 2025-11-20] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-22 | 8-K | Regulation FD disclosure; Other events |
| 2026-09-18 | 8-K | Listing notice or transfer |
| 2026-07-29 | 10-Q | Quarterly report |
| 2026-07-29 | 8-K | Results of operations |
| 2026-06-15 | 8-K | Director or officer change; Shareholder vote results |
| 2026-05-07 | 10-Q | Quarterly report |
| 2026-05-07 | 8-K | Results of operations |
| 2026-04-28 | DEF 14A | Proxy statement |
| 2026-04-28 | 8-K | Director or officer change |
| 2026-03-12 | 10-K | Annual report |
| 2026-03-12 | 8-K | Results of operations |
| 2026-03-10 | 8-K | Charter, bylaws or fiscal year change; Regulation FD disclosure |
Alerts for $FLNA
Email me when Filana Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.